NephroPlus

Hyderabad, India Founded: 2009 • Age: 17 yrs Listed
Dialysis services and technician training are provided for kidney care.
Request Access
Report Incorrect Data
Page last updated

About NephroPlus

NephroPlus is a publicly listed company based in Hyderabad (India) founded in 2009 by Pullaiah Vuppala, Vikram Vuppala, and Kamal D Shah. Dialysis services and technician training are provided for kidney care. NephroPlus has raised $205.37 million across 13 funding rounds from investors including Bessemer Venture Partners, International Finance Corporation and Asian Development Bank. The company has 1,707 employees. NephroPlus has completed 3 acquisitions, including DaVita India, Royal Care Dialysis Center and royalcaredialysis.com. NephroPlus was last valued at $236.37 million in December 2021. Its chief executive, as recorded, is Rohit Singh. Its website nephroplus.com draws about 25 thousand monthly visits. Its Indian entity Nephrocare Health Services Limited reported revenue of ₹1,023 Cr. NephroPlus offers products and services including In-Clinic Dialysis, Dialysis on Call, Home Hemodialysis, Holiday Dialysis, and Dialysis on Wheels. Its focus areas include Clinic Chains, Specialty Clinics and Dialysis Clinics. Its competitors include DCDC, Apex Kidney Care and VitusCare; 3 of its 3 listed competitors have raised funding.

Company details

NephroPlus was founded in 2009 in Hyderabad, India, as a provider in the healthcare sector focused on dialysis. Services are delivered through in-clinic, at-home, and mobile formats to support patients with kidney disease. A training academy is maintained for dialysis technicians and nurses. Educational resources and support programs are extended to enhance patient management of chronic conditions. Operations are centered in India with an emphasis on clinical standards.

  • Headquarters Hyderabad, India
  • Employees 1,707
  • Founders Pullaiah Vuppala, Vikram Vuppala, Kamal D Shah
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website nephroplus.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Nephrocare Health Services Limited
Operational Areas
Healthcare → Hospitals & Clinical Care
Key Metrics
  • Market Cap
    ₹5,998 Cr

    NEPHROPLUS · NSE

  • Share Price
    ₹607.40

    +1.84% today

  • Revenue
    ₹999 Cr

    FY 2025-26 · +32.2% YoY

  • EBITDA
    ₹224 Cr

    Margin 22.4%

  • Net Profit
    ₹74.89 Cr

    FY 2025-26 · +11.6% YoY

  • P/E (TTM)
    70.5x

    P/B 5.4x

  • ROE
    8.9%

    ROCE 15.2%

  • Debt / Equity
    0.20

    Interest cover 45.2x

  • Total Equity Funding
    $205.37M (USD)

    in 13 rounds

  • Latest Funding Round
    $103M (USD), Series F

    May 2024

  • Investors
    Bessemer Venture Partners

    & 24 more

  • Employee Count
    1,707
  • Investments & Acquisitions
    DaVita India

    & 2 more

Products & Services of NephroPlus

NephroPlus offers a comprehensive portfolio of products and services, including In-Clinic Dialysis, Dialysis on Call, Home Hemodialysis, Holiday Dialysis, and Dialysis on Wheels.

In-Clinic Dialysis
Dialysis Services

Provides safe dialysis in clinical settings for kidney patients.

Dialysis on Call
Dialysis Services

Offers convenient, on-demand dialysis at any location.

Home Hemodialysis
Dialysis Services

Delivers dialysis care directly in patients' homes.

Holiday Dialysis
Dialysis Services

Supports dialysis during travel at various destinations.

Dialysis on Wheels
Dialysis Services

Provides mobile dialysis for easy access anywhere.

Apps and channels of NephroPlus

NephroPlus publishes 1 mobile app with over 5K+ downloads; its YouTube channel NephroPlus Dialysis Centres has 16.7K subscribers and 30 videos.

NephroPlus
Google Play Medical Everyone Free 5K+ downloads
Developer: NephroPlus App
View on Google Play
NephroPlus Dialysis Centres
YouTube 16.7K subscribers 30 videos Howto & Style
Open channel

Videos from NephroPlus

The most watched videos on NephroPlus's YouTube channel, NephroPlus Dialysis Centres (16.7K subscribers). Click a video to play it here.

I Tried the VIRAL Raw Mango Curry – Here’s What Happened! 🤯
59.3K views
Lauki ke Kofte | Restaurant Style Bottle Gourd Kofta Curry
39.9K views
Ditch Coffee? Try Roasted Barley Tea #trending #shorts
25.4K views
Wheat Momos Recipe 🌾 | Guilt-Free Street Food You’ll Love!
20.2K views

More on NephroPlus Dialysis Centres.

Funding Insights of NephroPlus

NephroPlus has successfully raised a total of $205.37M across 13 strategic funding rounds. The most recent funding activity was a Series F round of $103 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $205.37M
  • Total Rounds 13
  • Last Round Series F — $103M
  • First Round $146,218

    (Aug 2010)

  • Investors Count 25

Latest 10 of 13 funding rounds of NephroPlus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2024$103MSeries F–Quadria Capital
Edoras Investment Holding
Jan 2023$8.4MDebt – Conventional––
Asian Development Bank
Dec 2021$25MSeries E$236.37M360 One
Investcorp, Bessemer Venture Partners
Dec 2021$2.28MAngel Round$149.26M–
Niraj Didwania, Vikram Vuppala
Feb 2021$137,678Angel Round$•••••Om Prakash Manchanda
–
Nov 2019$45MSeries D$•••••Investcorp, Healthcare Parent
SeaLink Capital Partners, Bessemer Venture Partners
Aug 2016$15MSeries C$•••••SeaLink Capital Partners
IFC
Dec 2015$937,638Debt – Venture––
Trifecta Capital
Oct 2015$138,280Series B$•••••Trifecta Capital
–
Mar 2014$10.19MSeries B$•••••IFC
Bessemer Venture Partners
Valuation history
DateValuationStage
Dec 2021$236.37M••••••••
Dec 2021$149.26M••••••••
Feb 2021$•••••••••••••
Nov 2019$•••••••••••••
Aug 2016$•••••••••••••
Oct 2015$•••••••••••••
Mar 2014$•••••••••••••
Nov 2011$•••••••••••••
Premium access

Full valuation and stage history of NephroPlus

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $236.37M (Dec 2021). 25 investors in total: 10 institutional and 15 angel.

Investors in NephroPlus

NephroPlus has secured backing from 25 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Bessemer Venture Partners, International Finance Corporation and Asian Development Bank.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Quadria Capital
Healthcare private equity investments focused on Asian markets.
2012quadriacapital.comSingapore, Singapore
Investcorp
Private equity, real estate, and credit investments are managed globally.
investcorp.comNew York, United States
Bessemer Venture Partners
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
1911bvp.comRedwood City, United States
SeaLink Capital Partners
Mergers and acquisitions are targeted by this private equity firm.
sealinkcap.comMumbai, India
International Finance Corporation
IFC is focused on private sector development in emerging markets.
1956ifc.org
Trifecta Capital
Private debt and equity funds are managed for technology sectors.
trifectacapital.inGurugram, India
Edoras Investment Holding
edorasinvestmentholding.tcc.mode
Asian Development Bank
Advisory services and financial resources are mobilized for development projects.
1966adb.orgMandaluyong, Philippines
360 One
Asset and wealth management software is provided for businesses.
2008360.oneMumbai, India
Healthcare Parent
Chain of dialysis clinics
healthcareparent.tcc.modeEbene City, Mauritius
Premium access

Investor details for NephroPlus

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Nephrocare Health Services Limited (NephroPlus)

Nephrocare Health Services Limited is the primary company behind NephroPlus. The board of Nephrocare Health Services Limited currently have 8 directors; the longest-serving is Vikram Vuppala, appointed in 2009. 24 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Vikram Vuppala
DIN 02847323
Managing Director18 Dec 200916 yrs 10 moNephrocare Health Services Limited
Vishal Vijay Gupta
DIN 01913013
Nominee Director10 Oct 201412 yrsNephrocare Health Services Limited
Gaurav Sharma
DIN 03311656
Nominee Director27 Nov 20196 yrs 10 moNephrocare Health Services Limited
Om Prakash Manchanda
DIN 02099404
Director11 Feb 20215 yrs 8 moNephrocare Health Services Limited
Hemant Sultania
DIN 00472577
Director18 Jun 20224 yrs 4 moNephrocare Health Services Limited
Sunil Kumar Thakur
DIN 03266370
Nominee Director08 May 20242 yrs 5 moNephrocare Health Services Limited
Ajay Bakshi
DIN 05254187
Director12 May 20251 yr 5 moNephrocare Health Services Limited
Annette Berit Ingrid Kumlien
DIN 11050620
Director12 May 20251 yr 5 moNephrocare Health Services Limited

People of NephroPlus

42 people are tracked at NephroPlus (11 in leadership, 8 in board & advisors, 23 in team); the tracked headcount is 1,707.

NameRoleGroup
Pullaiah Vuppala
Co-FounderLeadership
Vikram Vuppala
Co-Founder & Managing DirectorLeadership
Kamal D Shah
Co-Founder & Head of TechnologyLeadership
Rohit Singh
Co-CEOLeadership
Sukaran Singh Saluja
Co-CEOLeadership
Ravee Diksshit
VP, International OperationsLeadership
Pavanesh Tiwari
Vice President - Business DevelopmentLeadership
Karthik Varma Yalala
Associate General Manager - ITLeadership
Rajan Nayyar
Head Business Operations And Strategic InitiativesLeadership
Narayanan Rv
Deputy General Director - Nephrocare Health Services Central Asia LLCLeadership
Aravind Chunduru
Business Head APLeadership
Avinash Ignatius
Scientific AdvisorBoard & advisors
Om Manchanda
DirectorBoard & advisors
Karthik Tiruvarur
Nominee DirectorBoard & advisors
Hemant Sultania
Independent DirectorBoard & advisors
Gaurav Sharma
DirectorBoard & advisors
Umesh B Khanna
Scientific AdvisorBoard & advisors
Vishal Gupta
DirectorBoard & advisors
Vivekanand Jha
Chairman, Scientific Advisory BoardBoard & advisors
Dr.vidya Joshi
AGMTeam

22 more people are available in the full profile.

Premium access

Complete people profiles for NephroPlus

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of NephroPlus

NephroPlus is a publicly listed company on the NSE with ticker symbol NEPHROPLUS in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date17 Dec 2025
  • Listed onBSE: 544647 · NSE: NEPHROPLUS
  • Listed entityNephrocare Health Services Limited
  • Exchange sectorHealth services
  • ISININE428V01029
  • Share price₹622.75 (+0.29% on the day) · 2026-10-14
  • Market capitalisation₹6,236 Cr
  • Volume (last session)83,996

Financials of NephroPlus

Exchange-reported figures of Nephrocare Health Services Limited, the listed company behind NephroPlus (NSE: NEPHROPLUS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹999 Cr
+32.2% YoY
EBITDA
₹224 Cr
+34.3% YoY
Profit After Tax
₹74.89 Cr
+11.6% YoY
Net Worth
₹1,116 Cr
+91.1% YoY
Total Assets
₹1,202 Cr
+41.9% YoY
Total Debt
₹79.71 Cr
-69.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue999756566437318286
Revenue growth+32.2%+33.5%+29.5%+37.7%+11.2%-
EBITDA22416710148.6016.1237.41
EBITDA margin+22.4%+22.1%+17.8%+11.1%+5.1%+13.1%
Profit before tax97.4687.4433.17(8.59)(27.16)0.90
Net profit74.8967.1035.20(11.78)(21.34)0.62
Net profit margin+7.5%+8.9%+6.2%-2.7%-6.7%+0.2%
EPS (₹)7.66380.15200.87(67.75)(123.56)3.84
Balance sheet
Total assets1,202847689606527404
Net worth1,116584414389396249
Total debt79.71258268196115137
Cash & bank25515561.1712714364.58
Net working capital404348273264241154
Cash flow
Cash from operations23313572.2811.2714.3531.54
Cash from investing(392)(125)(51.93)(75.73)(130)(62.07)
Cash from financing15754.3726.7459.9712135.80
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue282266260246228219197
Revenue growth (YoY)+23.7%+21.2%+31.7%----
Other income7.4611.573.323.896.584.115.37
EBITDA60.3150.6860.8763.9347.5651.3044.10
EBITDA margin+21.4%+19.1%+23.4%+26.0%+20.9%+23.4%+22.4%
Depreciation24.5425.8521.8623.4419.5219.3818.17
Interest2.213.185.9645.006.106.124.85
Profit before tax41.0233.2236.37(0.62)28.5229.9126.45
Tax9.062.854.128.854.815.066.32
Net profit31.9630.3732.25(9.47)23.7124.8520.13
EPS (₹)3.112.963.35(1.12)2.702.952.39
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue630544436386317284
Revenue growth+15.9%+24.6%+13.0%+21.8%+11.4%-
EBITDA88.1594.8951.9737.9717.8637.73
EBITDA margin+14.0%+17.5%+11.9%+9.8%+5.6%+13.3%
Profit before tax(3.79)45.360.22(12.88)(28.09)1.29
Net profit(10.43)34.233.96(15.47)(21.99)1.01
Net profit margin-1.7%+6.3%+0.9%-4.0%-6.9%+0.4%
EPS (₹)(0.80)193.9722.20(88.88)(127.32)6.28
Balance sheet
Total assets989681594605537394
Net worth971542404397412250
Total debt11.72133178196115137
Cash & bank22533.421.643.2212863.52
Net working capital326205186240220149
Cash flow
Cash from operations13379.7356.7511.1411.9232.55
Cash from investing(299)(104)(22.67)(74.71)(167)(64.15)
Cash from financing25626.02(35.54)63.3914735.80
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue170164161156149145138
Revenue growth (YoY)+14.5%+13.3%+16.2%----
Other income6.126.143.462.872.972.733.91
Total expenses146142138132129123116
EBITDA24.1422.0722.8623.4719.7521.7522.46
EBITDA margin+14.2%+13.4%+14.2%+15.1%+13.3%+15.0%+16.3%
Depreciation13.0915.9513.4115.9112.3513.3912.17
Interest0.491.273.9641.053.483.683.40
Profit before tax16.6810.998.95(30.62)6.897.4110.80
Tax4.130.110.511.801.891.752.68

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue282266260246228219197
Revenue growth (YoY)+23.7%+21.2%+31.7%----
Other income7.4611.573.323.896.584.115.37
EBITDA60.3150.6860.8763.9347.5651.3044.10
EBITDA margin+21.4%+19.1%+23.4%+26.0%+20.9%+23.4%+22.4%
Depreciation24.5425.8521.8623.4419.5219.3818.17
Interest2.213.185.9645.006.106.124.85
Profit before tax41.0233.2236.37(0.62)28.5229.9126.45
Tax9.062.854.128.854.815.066.32
Net profit31.9630.3732.25(9.47)23.7124.8520.13
EPS (₹)3.112.963.35(1.12)2.702.952.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue999756566437318286
Revenue growth+32.2%+33.5%+29.5%+37.7%+11.2%-
Other income24.5114.108.575.969.534.75
Total expenses775589465389302248
Employee cost17212391.3996.6977.0969.72
EBITDA22416710148.6016.1237.41
EBITDA margin+22.4%+22.1%+17.8%+11.1%+5.1%+13.1%
Depreciation90.6772.4756.1146.8842.5033.89
Interest60.2420.8320.1816.2710.317.37
Profit before tax97.4687.4433.17(8.59)(27.16)0.90
Tax20.6320.34(1.97)3.19(5.82)0.28
Net profit74.8967.1035.20(11.78)(21.34)0.62
Net profit margin+7.5%+8.9%+6.2%-2.7%-6.7%+0.2%
EPS (₹)7.66380.15200.87(67.75)(123.56)3.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital20.075.435.145.145.124.44
Reserves & surplus1,096579409384387245
Shareholders' funds (net worth)1,116584414389396249
Minority interest0.000.000.000.000.009.88
Secured loans22.98226243219115137
Unsecured loans56.7332.2524.48(23.09)0.000.00
Total debt79.71258268196115137
Total liabilities1,202847689606527404
Assets
Gross block841679564384306253
Net block517396356239205192
Capital work in progress5.785.840.6933.8442.992.23
Investments17850.760.000.000.000.00
Inventories33.0426.6225.9126.2714.5816.03
Sundry debtors31726620315910779.25
Cash & bank balances25515561.1712714364.58
Loans & advances63.1446.1710012.1819.4918.47
Total current assets669495390324285178
Total current liabilities26514711759.8843.6324.41
Net working capital404348273264241154
Total assets1,202847689606527404
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash12661.1514.0618.5512.527.25
Net cash from operating activities23313572.2811.2714.3531.54
Net cash from investing activities(392)(125)(51.93)(75.73)(130)(62.07)
Net cash from financing activities15754.3726.7459.9712135.80
Net change in cash(1.93)64.6747.09(4.49)6.045.26
Closing cash25515561.1712714364.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+32.2%+33.5%+29.5%+37.7%+11.2%-
EBITDA growth+34.3%+65.2%+107.6%+201.5%-56.9%-
PBT growth+11.5%+163.6%+9998.0%+68.4%-+9997.0%
Net income growth+11.6%+90.6%+398.8%+44.8%-3541.9%-
Revenue CAGR (3Y)+31.7%+33.5%+25.6%---
EBITDA CAGR (3Y)+66.4%+117.8%+39.2%---
Profitability & leverage
Net income margin+7.7%+8.9%+6.2%-2.7%-6.7%+0.2%
Return on capital employed+15.2%+13.0%+7.7%0.0%0.0%+1.7%
Return on net worth+8.9%+12.0%+7.9%0.0%0.0%+0.2%
Debt / equity0.200.530.580.400.390.55
Long-term debt / equity0.100.270.320.220.210.27
Interest cover45.2322.1245.06945.93-39.08209.38
Efficiency & per share
Fixed asset turnover1.311.221.191.271.141.13
Inventory turnover33.4828.7821.7021.4120.7617.83
Debtors turnover3.423.223.143.293.413.61
EPS (₹)7.66380.15200.87(67.75)(123.56)3.84
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)111.273,288.652,345.992,213.962,254.311,546.19
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue170164161156149145138
Revenue growth (YoY)+14.5%+13.3%+16.2%----
Other income6.126.143.462.872.972.733.91
Total expenses146142138132129123116
EBITDA24.1422.0722.8623.4719.7521.7522.46
EBITDA margin+14.2%+13.4%+14.2%+15.1%+13.3%+15.0%+16.3%
Depreciation13.0915.9513.4115.9112.3513.3912.17
Interest0.491.273.9641.053.483.683.40
Profit before tax16.6810.998.95(30.62)6.897.4110.80
Tax4.130.110.511.801.891.752.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue630544436386317284
Revenue growth+15.9%+24.6%+13.0%+21.8%+11.4%-
Other income15.4315.637.805.093.564.75
Total expenses542449384348299247
Employee cost12192.6671.5584.8076.0569.72
EBITDA88.1594.8951.9737.9717.8637.73
EBITDA margin+14.0%+17.5%+11.9%+9.8%+5.6%+13.3%
Depreciation57.6150.8642.7340.9139.2733.83
Interest49.7614.3016.8215.0310.247.36
Profit before tax(3.79)45.360.22(12.88)(28.09)1.29
Tax4.2911.13(3.67)2.59(6.10)0.28
Net profit(10.43)34.233.96(15.47)(21.99)1.01
Net profit margin-1.7%+6.3%+0.9%-4.0%-6.9%+0.4%
EPS (₹)(0.80)193.9722.20(88.88)(127.32)6.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital20.071.775.145.145.124.44
Reserves & surplus951537399392403246
Shareholders' funds (net worth)971542404397412250
Secured loans0.43123178219115137
Unsecured loans11.2910.610.00(23.09)0.000.00
Total debt11.72133178196115137
Total liabilities989681594605537394
Assets
Gross block473455397313272227
Net block245234219169167159
Capital work in progress3.744.300.692.632.180.00
Investments33521214914811047.47
Inventories18.1317.5819.2822.1714.3416.03
Sundry debtors21819413812991.7676.64
Cash & bank balances22533.421.643.2212863.52
Loans & advances11.0435.7897.5112820.8017.09
Total current assets472280257283255173
Total current liabilities14675.7070.5542.1334.6424.31
Net working capital326205186240220149
Total assets989681594605537394
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash3.851.623.083.2611.457.25
Net cash from operating activities13379.7356.7511.1411.9232.55
Net cash from investing activities(299)(104)(22.67)(74.71)(167)(64.15)
Net cash from financing activities25626.02(35.54)63.3914735.80
Net change in cash89.822.23(1.46)(0.18)(8.20)4.20
Closing cash22533.421.643.2212863.52
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+15.9%+24.6%+13.0%+21.8%+11.4%-
EBITDA growth-7.1%+82.6%+36.9%+112.6%-52.7%-
PBT growth--+9998.0%+54.2%-+9997.0%
Net income growth-130.5%+764.4%+125.6%+29.7%-2277.2%-
Revenue CAGR (3Y)+17.7%+19.7%+15.3%---
EBITDA CAGR (3Y)+32.4%+74.5%+11.3%---
Profitability & leverage
Net income margin-1.3%+6.3%+0.9%-4.0%-6.9%+0.4%
Return on capital employed0.0%+8.1%+2.6%0.0%0.0%+1.8%
Return on net worth0.0%+6.0%+0.9%0.0%0.0%+0.3%
Debt / equity0.100.330.470.390.380.55
Long-term debt / equity0.040.120.180.180.200.27
Interest cover162.9332.48182.03-511.22-47.83188.72
Efficiency & per share
Fixed asset turnover1.361.281.231.321.271.26
Inventory turnover35.2729.5021.0521.1520.8717.75
Debtors turnover3.063.283.273.503.763.71
EPS (₹)(0.80)193.9722.20(88.88)(127.32)6.28
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)96.763,050.092,291.712,260.062,346.991,550.56

Investments & Acquisitions by NephroPlus

NephroPlus has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include DaVita India, Royal Care Dialysis Center and royalcaredialysis.com.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Royal Care Dialysis Center
Chain of dialysis clinics
royalcaredialysiscenter.comQuezon, Philippines2013Oct 2020••••
royalcaredialysis.com
Dialysis services are offered in Talisay, Philippines.
royalcaredialysis.comTalisay, Philippines2019Oct 2020••••
DaVita India
Provider of online medication information and resources. It offers detailed information on various medications, including uses, prices, composition, side effects, and dosages. The platform aims to empower individuals to make informed healthcare decisions by providing accessible and accurate medical details. It serves patients, caregivers, and healthcare professionals, supporting their health choices with reliable and concise information. The platform includes editorial and fact-checking policies to ensure accuracy and completeness.
davita.inBengaluru, India2009Nov 2018••••
Premium access

Complete acquisition details for NephroPlus

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of NephroPlus

8 dated milestones of NephroPlus across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded NephroPlus is founded.
  2. Funding First funding round of $146K.
  3. Milestone Reaches Minicorn status.
  4. Acquisition Acquires DaVita India.
  5. Acquisition Acquires royalcaredialysis.com.
  6. Acquisition Acquires Royal Care Dialysis Center.
  7. Funding Latest funding round, Series F, of $103.0M.
  8. IPO Lists on the stock exchange (IPO).

Competitors of NephroPlus

NephroPlus has 3 listed competitors in our database, 3 of them funded. They include DCDC, Apex Kidney Care and VitusCare.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
DCDC
dcdc.co.in2009Delhi, India$61.43M850
Chain of dialysis and kidney clinics
Apex Kidney Care
apexkidneycare.com2008Mumbai, India$19.23M1,445
Chain of dialysis clinics
VitusCare
vituscare.com2017Gurugram, India$4.62M72
Chain of dialysis clinics
Premium access

Detailed competitors of NephroPlus

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of NephroPlus

The website of NephroPlus (nephroplus.com) receives about 25.4K visits a month.

  • Monthly visits
    25.4K

    ▼ 17.2% vs previous month

Similar websites

Websites whose visitors overlap most with NephroPlus. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Cytecare
cytecare.com
100%
15.2K#1,808,623View details
Nephrology Physicians
nephinc.com
86%
#4,375,124View details
DaVita India
davita.in
85%
View details
Kidney Patient Guide
kidneypatientguide.org.uk
84%
#4,030,753View details
NephroCare
nephrocare.com
75%
45.8K#711,548View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 22 similar websites and full traffic analytics for NephroPlus

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 22 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Hospitals & Clinical Care

3 companies that operate in the same segment as NephroPlus (Hospitals & Clinical Care) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Cloudnine
Maternity, childcare, and fertility services are delivered via hospital chains.
2007Bengaluru, Karnataka, IndiaUSD 204.87 MUSD 140.46 M4,459
HCG
Chain of oncology hospitals
1989Bengaluru, Karnataka, IndiaUSD 36.59 MUSD 270.51 M8,400
Medanta
Chain of multi-super specialty healthcare hospitals
2004Gurugram, Haryana, IndiaUSD 104.7 MUSD 461.72 M12,240
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nephroplus

NEPHROPLUS: RS. 409.20 CRORES NSE BLOCK TRADE; FOR ~ 5,780,499 SHARES, AT RS. 707.90
Exchange Update • 1 month ago
Nephrocare Health Services Block Deal: Investors likely to sell 9% stake at ₹705/share - CNBC TV18
CNBCTV18 • 1 month ago
Nephrocare Health Services: Plans Analyst And Investor Meeting On September 29 At 1 PM
Exchange Update • 1 month ago
Nephrocare Health: Plans To Buy Dialysis Facility Assets In The Philippines For ₹10.25 Crore.
Exchange Update • 1 month ago
NephroPlus Launches International Dialysis Academy
IndiaMedToday • 1 month ago
'Buy' Nephrocare Health Services for 16% upside, says ICICI Securities; check share price target | Stock Market News
mint • 1 month ago
Buy Nephrocare Health Services; target of Rs 825: ICICI Securities
Moneycontrol • 1 month ago
Nephrocare Health's Unit Got Order For Review Of Tax Audit From Tashkent City Tax Department, Uzbekistan
Reuters • 1 month ago
Nephrocare Health Services Buys Dialysis Center Assets In Leyte
Reuters • 2 months ago
Nephrocare Health Services Ltd Says Step-Down Unit Entered Into Asset Transfer Agreement With Juan Nephro Dialysis Center
Reuters • 2 months ago
Premium access

Complete news archive for NephroPlus

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about NephroPlus

NephroPlus was founded in 2009 and raised its 1st funding round 1 year after it was founded.

NephroPlus is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Rohit Singh is the CEO of NephroPlus, as recorded in our data.

NephroPlus is a funded company, having raised a total of $205.37M across 13 funding rounds to date. The company's 1st funding round was a Series B of $10.19M, raised on Aug 2010.

NephroPlus has 1,707 employees.

The primary company behind NephroPlus, Nephrocare Health Services Limited, reported revenue of ₹1,023 Cr for FY 2026, up 32% year on year.

NephroPlus was founded in 2009 in Hyderabad, India, as a provider in the healthcare sector focused on dialysis. Services are delivered through in-clinic, at-home, and mobile formats to support patients with kidney disease. A training academy is maintained for dialysis technicians and nurses. Educational resources and support programs are extended to enhance patient management of chronic conditions. Operations are centered in India with an emphasis on clinical standards.

NephroPlus's top competitors include DCDC, Apex Kidney Care and VitusCare.

NephroPlus offers In-Clinic Dialysis, Dialysis on Call, Home Hemodialysis, Holiday Dialysis, and Dialysis on Wheels.

Yes, NephroPlus is publicly traded on NSE under the ticker symbol NEPHROPLUS.

NephroPlus has made 3 acquisitions, including DaVita India, Royal Care Dialysis Center, and royalcaredialysis.com.

NephroPlus has 25 investors. Key investors include Bessemer Venture Partners, International Finance Corporation, Asian Development Bank, 360 One, and Quadria Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available